Suchergebnisse
10
Alles
Such-Filter
Organisationen
Palisade Bio, Inc.
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
14. März 2025 08:30 ET
|
Palisade Bio, Inc.
Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious...
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
12. März 2025 08:30 ET
|
Palisade Bio, Inc.
PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) --...
Palisade Bio Participates in Virtual Investor “What This Means” Segment
04. März 2025 08:30 ET
|
Palisade Bio, Inc.
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) Carlsbad,...
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
20. Februar 2025 08:45 ET
|
Palisade Bio, Inc.
Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108...
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
19. Februar 2025 09:00 ET
|
Palisade Bio, Inc.
On-demand video webcast now available here Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage...
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
10. Februar 2025 08:45 ET
|
Palisade Bio, Inc.
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure ...
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
29. Januar 2025 08:45 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
22. Januar 2025 08:00 ET
|
Palisade Bio, Inc.
Live webcast on Wednesday, January 29th at 2:20 PM ET Carlsbad, CA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a...
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
16. Januar 2025 08:00 ET
|
Palisade Bio, Inc.
Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of...
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03. Januar 2025 17:20 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing...